Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.77 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3377765 | 0.88 | MAPK14 (0.61) | MAPK14RIPK2SCN9APTPN1 | |
| SCHEMBL1691549 | 0.88 | MAPK14 (0.72) | MAPK14RIPK2SCN9ALCKCYP2C9 | |
| SCHEMBL12000959 | 0.87 | MAPK14 (0.71) | MAPK14RIPK2SCN9ALCKCYP2C9 | |
| SCHEMBL20209701 | 0.87 | MAPK14 (0.71) | MAPK14RIPK2SCN9ALCKCYP2C9 | |
| SCHEMBL13184789 | 0.87 | MAPK14 (0.71) | MAPK14RIPK2SCN9ALCKCYP2C9 | |
| SCHEMBL18172047 | 0.86 | MAPK14 (0.59) | MAPK14RIPK2SCN9APTPN1NOTUM | |
| SCHEMBL3373162 | 0.83 | MAPK14 (0.55) | MAPK14RIPK2PTPN1POLBMAPT | |
| SCHEMBL20263149 | 0.83 | MAPK14 (0.66) | MAPK14RIPK2SCN9ALCKCYP2C9 | |
| SCHEMBL15930180 | 0.83 | MAPK14 (0.66) | MAPK14RIPK2SCN9ALCKCYP2C9 | |
| SCHEMBL13377946 | 0.83 | MAPK14 (0.70) | MAPK14SCN9ALCKCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105509-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2018-04-19 | — | — | US | disclosed |
| CN-101501003-B | Phenyl-pyrazole derivatives as non-steroidal glucocorticoid receptor ligands | GLAXO GROUP LTD | 2013-05-08 | — | — | CN | disclosed |
| US-20120277279-A1 | Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions | GLAXO GROUP LIMITED | 2012-11-01 | — | — | US | disclosed |
| US-8247377-B2 | Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions | GLAXO GROUP LIMITED (GB) | 2012-08-21 | — | — | US | disclosed |
| EP-2029549-B1 | PHENYL-PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORICOID RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2010-11-10 | — | — | EP | disclosed |
| EP-1618092-B1 | ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-09-22 | — | — | EP | disclosed |
| US-20100234441-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-20100035926-A1 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100016320-A1 | ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-21 | — | — | US | disclosed |
| US-20100016320-A1 | ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-21 | — | — | US | disclosed |
| US-7414056-B2 | Pyrazole-amide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-7396935-B2 | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396935-B2 | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| WO-2008074814-A1 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| US-7390810-B2 | Pyrazole-amine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390810-B2 | Pyrazole-amine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080108626-A1 | (5-amino-1-phenyl-1H-pyrazole)-(3-Amino-N-isoxazol-3-yl-4-methyl)-benzamide; p38 mitogen-activated protein kinase inhibitor; reduced levels of TNF- alpha expression; antiinfammatory agent: rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080108626-A1 | (5-amino-1-phenyl-1H-pyrazole)-(3-Amino-N-isoxazol-3-yl-4-methyl)-benzamide; p38 mitogen-activated protein kinase inhibitor; reduced levels of TNF- alpha expression; antiinfammatory agent: rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| WO-2008000777-A2 | PHENYL- PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | GLAXO GROUP LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007144327-A2 | PHENYL-PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234441-A1 | NOVEL COMPOUNDS | LTB4R2, TSLP, LTB4R | MAPK14 1393/4885RIPK2 1523/4885SCN9A 2443/4885 |
| US-20180105509-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | SCN7A, SCN1A, SCN1B | MAPK14 1579/4885RIPK2 3181/4885SCN9A 13/4885 |
| US-20100016320-A1 | ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAPK6, CDK6, GRK6 | MAPK14 62/4885RIPK2 705/4885SCN9A 2235/4885 |
| US-20080108626-A1 | (5-amino-1-phenyl-1H-pyrazole)-(3-Amino-N-isoxazol-3-yl-4-methyl)-benzamide; p38 mitogen-activated protein kinase inhibitor; reduced levels of TNF- alpha expression; antiinfammatory agent: rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease | MAPK1, MAPK3, TNF | MAPK14 15/4885RIPK2 77/4885SCN9A 4043/4885 |
| US-20100035926-A1 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | NR3C1, NR3C2, CYP11B2 | MAPK14 602/4885RIPK2 711/4885SCN9A 3917/4885 |
| US-20120277279-A1 | Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions | NR3C1, SERPINA6, PTGS1 | MAPK14 530/4885RIPK2 1695/4885SCN9A 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.